India, once called as the vaccine capital, is slowly losing its sheen because of various reasons, primarily the aggressive marketing strategy of China and Korea and the lacklustre policies of the government of India, say experts.
Vaccine exports from the country plunged by eight per cent during 2016-17 and nearly four per cent in the previous fiscal year.
India exported vaccines worth USD 653.40 million in 2017-18 while it was USD 679.28 million in 2016-17, according to data of the Pharmaceuticals Export Promotion Council, a body under the Ministry of Commerce.
Over 70 per cent of vaccines were exported based on UNICEF requirement, which recently changed its procurement policy from yearly indent to quarterly, resulting in uncertainty over production schedule, said chairman and managing director of Bharat Biotech Krishna Ella.
The method adopted by the international body on vaccine procurement gave an edge to Korea and China on price bargaining resulting in price erosion, Ella said.
Serum Institute of India, Bharat Biotech and Biological E Limited were the leading suppliers to UNICEF.
He said the government of India needs to shed bureaucracy-centric policies and develop science-oriented ones to encourage vaccine-manufacturers.
"The country should have a strategy, make policies and pricing transparent. Besides, the government should sit with the industry and take on China and Korea in the next five years. If the government does not do that, we would lose our grip on the vaccine market in another two years," Ella told PTI.
According to industry sources, some of the Korean companies such as LG Chem and Samsung were spending millions of dollars on expansion and modernising their facilities.
Koreans and Chinese have become aggressive, both were getting into the markets of developed countries which India has been exporting to, the sources said.
When contacted, Director General of Pharmexcil Uday Bhaskar said vaccine constituted 3.78 per cent of the total pharmaceutical exports last year.
Though there has been a negative growth of 10.25 per cent till February last year, it recovered in March and ended up at 3.81 per cent, Bhaskar said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
